$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

$shph Overview Financials Valuation SEC Filings Company Website

2024 Q4 Form 10-Q Financial Statement

#000149315224045176 Filed on November 13, 2024

Income Statement

Concept	2024 Q4	2024 Q3	2023 Q3
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin			$458.8K
YoY Change			201.02%
% of Gross Profit
Research & Development		$1.401M	$1.140M
YoY Change		22.82%	70.44%
% of Gross Profit
Depreciation & Amortization			$4.830K
YoY Change			205.7%
% of Gross Profit
Operating Expenses		$3.052M	$1.599M
YoY Change		90.82%	94.67%
Operating Profit		-$3.052M	-$1.599M
YoY Change		90.82%	94.67%
Interest Expense			-$150.2K
YoY Change			-70.3%
% of Operating Profit
Other Income/Expense, Net		-$732.5K	-$193.6K
YoY Change		278.35%	9.41%
Pretax Income			-$1.775M
YoY Change			77.81%
Income Tax
% Of Pretax Income
Net Earnings		-$3.784M	-$1.793M
YoY Change		111.08%	79.56%
Net Earnings / Revenue
Basic Earnings Per Share		-$1.59	-$0.11
Diluted Earnings Per Share		-$1.59	-$0.11
COMMON SHARES
Basic Shares Outstanding	3.665M shares	2.227M shares	15.73M shares
Diluted Shares Outstanding		2.384M shares	1.970M shares

Balance Sheet

Concept	2024 Q3	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments		$6.807M
YoY Change		-25.37%
Cash & Equivalents	$156.7K	$3.886M
Short-Term Investments		$2.921M
Other Short-Term Assets		$6.480K
YoY Change		-96.03%
Inventory
Prepaid Expenses	$103.0K	$170.1K
Receivables		$12.44K
Other Receivables		$0.00
Total Short-Term Assets	$361.4K	$6.996M
YoY Change	-94.83%	-24.69%
LONG-TERM ASSETS
Property, Plant & Equipment	$21.16K	$26.81K
YoY Change	-21.07%	90.41%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$312.2K	$380.2K
YoY Change	-17.88%	310.9%
TOTAL ASSETS
Total Short-Term Assets	$361.4K	$6.996M
Total Long-Term Assets	$312.2K	$380.2K
Total Assets	$673.6K	$7.376M
YoY Change	-90.87%	-21.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$180.0K
YoY Change		67.99%
Accrued Expenses		$167.6K
YoY Change		-5.75%
Deferred Revenue
YoY Change
Short-Term Debt		$0.00
YoY Change		-100.0%
Long-Term Debt Due		$462.8K
YoY Change
Total Short-Term Liabilities	$1.659M	$810.4K
YoY Change	104.73%	-16.49%
LONG-TERM LIABILITIES
Long-Term Debt		$134.4K
YoY Change
Other Long-Term Liabilities		$821.3K
YoY Change		12212.59%
Total Long-Term Liabilities		$955.6K
YoY Change		14227.29%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.659M	$810.4K
Total Long-Term Liabilities		$955.6K
Total Liabilities	$1.989M	$1.766M
YoY Change	12.62%	80.74%
SHAREHOLDERS EQUITY
Retained Earnings	-$32.98M	-$13.85M
YoY Change	138.17%	70.03%
Common Stock	$29.00	$160.00
YoY Change	-81.88%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$1.315M	$5.610M
YoY Change
Total Liabilities & Shareholders Equity	$673.6K	$7.376M
YoY Change	-90.87%	-21.38%

Cashflow Statement

Concept	2024 Q3	2023 Q3
OPERATING ACTIVITIES
Net Income	-$3.784M	-$1.793M
YoY Change	111.08%	79.56%
Depreciation, Depletion And Amortization		$4.830K
YoY Change		205.7%
Cash From Operating Activities		-$1.539M
YoY Change		46.49%
INVESTING ACTIVITIES
Capital Expenditures		$19.05K
YoY Change
Acquisitions
YoY Change
Other Investing Activities		-$7.710K
YoY Change
Cash From Investing Activities		-$26.76K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		4.530K
YoY Change		-99.96%
NET CHANGE
Cash From Operating Activities		-1.539M
Cash From Investing Activities		-26.76K
Cash From Financing Activities		4.530K
Net Change In Cash		-1.561M
YoY Change		-117.21%
FREE CASH FLOW
Cash From Operating Activities		-$1.539M
Capital Expenditures		$19.05K
Free Cash Flow		-$1.558M
YoY Change		48.3%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Revenues Revenues		usd
	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1045177	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2632387	usd
CY2024Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	328995	usd
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
CY2024Q3	us-gaap	Assets Assets	673568	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156656	usd
CY2024Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	103040	usd
CY2024Q3	us-gaap	Interest Receivable Current InterestReceivableCurrent	4	usd
CY2024Q3	us-gaap	Assets Current AssetsCurrent	361351	usd
CY2024Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21160	usd
CY2024Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	291057	usd
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Central Index Key EntityCentralIndexKey	0001757499
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2024Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2024Q3	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2024Q3	us-gaap	Revenues Revenues		usd
CY2023Q3	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2024Q3	SHPH	Finance Fee FinanceFee		usd
CY2023Q3	SHPH	Finance Fee FinanceFee		usd
	SHPH	Finance Fee FinanceFee		usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
CY2024Q3	SHPH	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		usd
CY2023Q3	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt		usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts		usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts		usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees		usd
	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability		usd
	us-gaap	Revenues Revenues		usd
CY2024Q3	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent		usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2024Q3	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure		usd
CY2024Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2023Q3	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability		usd
CY2024Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-41488
	dei	Entity Registrant Name EntityRegistrantName	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-5089826
	dei	Entity Address Address Line1 EntityAddressAddressLine1	401 Professional Drive
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 260
	dei	Entity Address City Or Town EntityAddressCityOrTown	Gaithersburg
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MD
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	20879
	dei	City Area Code CityAreaCode	(240)
	dei	Local Phone Number LocalPhoneNumber	403-4212
	dei	Security12b Title Security12bTitle	Common Stock
	dei	Trading Symbol TradingSymbol	SHPH
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	3664919	shares
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2576416	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	114473	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2887215	usd
CY2023Q4	us-gaap	Interest Receivable Current InterestReceivableCurrent	14901	usd
CY2024Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	101651	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5593005	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	24827	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	333904	usd
CY2023Q4	us-gaap	Assets Assets	5951736	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	595999	usd
CY2024Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	58652	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	52479	usd
CY2024Q3	us-gaap	Liabilities Current LiabilitiesCurrent	1659233	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1042237	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	135089	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	74107	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	414512	usd
CY2024Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	255605	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	304127	usd
CY2024Q3	us-gaap	Liabilities Liabilities	1988945	usd
CY2023Q4	us-gaap	Liabilities Liabilities	1895965	usd
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference PreferredStockLiquidationPreference	1000
CY2024Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2024Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2946099	shares
CY2024Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2946099	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2008689	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2008689	shares
CY2024Q3	us-gaap	Common Stock Value CommonStockValue	29	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	20	usd
CY2024Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	31664226	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	29489055	usd
CY2024Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-32979632	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-25433304	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1315377	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4055771	usd
CY2024Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	673568	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	5951736	usd
CY2024Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1400564	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2806644	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	265553	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	963642	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	730186	usd
CY2024Q3	us-gaap	Legal Fees LegalFees	1322002	usd
CY2023Q3	us-gaap	Legal Fees LegalFees	288416	usd
	us-gaap	Legal Fees LegalFees	2323013	usd
	us-gaap	Legal Fees LegalFees	1072728	usd
CY2024Q3	us-gaap	Operating Expenses OperatingExpenses	3051561	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	1599146	usd
	us-gaap	Operating Expenses OperatingExpenses	5919042	usd
	us-gaap	Operating Expenses OperatingExpenses	4609558	usd
CY2024Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3051561	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1599146	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-5919042	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-4609558	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2524	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	20765	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	38135	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	56720	usd
	SHPH	Finance Fee FinanceFee	104245	usd
CY2024Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	286316	usd
CY2023Q3	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	442900	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	340405	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2118175	usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	56398	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	100118	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1744	usd
CY2024Q3	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-42898	usd
CY2023Q3	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	9606	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-71568	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	21134	usd
CY2024Q3	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	762186	usd
CY2023Q3	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	43414	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	833501	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	477221	usd
CY2024Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-732521	usd
CY2023Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-193608	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1627286	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-342665	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3784082	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1792754	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7546328	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4952223	usd
CY2024Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2384177	shares
CY2024Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2384177	shares
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1969904	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1969904	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2189366	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2189366	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1820006	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1820006	shares
CY2024Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.59
CY2024Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.59
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.91
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.91
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.45
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.45
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.72
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.72
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	4055771	usd
CY2024Q1	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	325298	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	111449	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1731031	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	2761487	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	71162	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-2031215	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	801434	usd
CY2024Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1621996	usd
CY2024Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	45275	usd
CY2024Q3	us-gaap	Net Income Loss NetIncomeLoss	-3784082	usd
CY2024Q3	us-gaap	Stockholders Equity StockholdersEquity	-1315377	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	7677869	usd
CY2023Q1	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	8727	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	90816	usd
CY2023Q1	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	104547	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8333	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-975097	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	6906468	usd
CY2023Q2	SHPH	Stock Issued During Period Value Conversion Of Accrued Interest And Principal StockIssuedDuringPeriodValueConversionOfAccruedInterestAndPrincipal	2163992	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	49522	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-2184372	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6935610	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	6935610	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	429310	usd
CY2023Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	37583	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-1792754	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	5609749	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	5609749	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7546328	usd
	us-gaap	Net Income Loss NetIncomeLoss	-4952223	usd
	us-gaap	Depreciation Depreciation	3667	usd
	us-gaap	Depreciation Depreciation	4828	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	340405	usd
	us-gaap	Derivative Gain Loss On Derivative Net DerivativeGainLossOnDerivativeNet	2118175	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1079444	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	1654724	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	100118	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1744	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	-71568	usd
	us-gaap	Marketable Securities Gain Loss Excluding Other Than Temporary Impairments MarketableSecuritiesGainLossExcludingOtherThanTemporaryImpairments	21134	usd
	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	54670	usd
	SHPH	Accrued Interest Settled With Common Stock AccruedInterestSettledWithCommonStock	294927	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	833501	usd
	SHPH	Loss On Settlement Of Convertible Debt LossOnSettlementOfConvertibleDebt	477221	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	227886	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	95438	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	-14897	usd
	us-gaap	Increase Decrease In Accrued Interest Receivable Net IncreaseDecreaseInAccruedInterestReceivableNet	12435	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	-11433	usd
	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	8956	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1065584	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	63255	usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-446	usd
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	-12500	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	-15056	usd
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	106578	usd
	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	2137	usd
	SHPH	Increase Decrease In Accrued Interest Payable Related Parties IncreaseDecreaseInAccruedInterestPayableRelatedParties	-98135	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	498	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	9358	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4637068	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4518973	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	43587	usd
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	2977714	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	2959352	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	80000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	19046	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	2915765	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2916760	usd
	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	250000	usd
	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	685473	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	3935000	usd
	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	345000	usd
	us-gaap	Payments Of Financing Costs PaymentsOfFinancingCosts	101651	usd
	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	846806	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-698457	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2904527	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2419760	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4531206	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2576416	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	8417203	usd
CY2024Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	156656	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3885997	usd
	us-gaap	Interest Paid Net InterestPaidNet	79682	usd
	us-gaap	Interest Paid Net InterestPaidNet	102373	usd
	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	1947294	usd
	SHPH	Common Stock Issued For Settlement Of Debt CommonStockIssuedForSettlementOfDebt	2697849	usd
	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	0	usd
	SHPH	Warrants Issuance Fees WarrantsIssuanceFees	8727	usd
	SHPH	Warrants Issued For Financing Fees WarrantsIssuedForFinancingFees	90816	usd
	SHPH	Initial Recognition Of Right Of Use Asset And Liability InitialRecognitionOfRightOfUseAssetAndLiability	365556	usd
	us-gaap	Net Income Loss NetIncomeLoss	-7500000	usd
	SHPH	Working Capital WorkingCapital	1300000	usd
CY2024Q3	us-gaap	Share Price SharePrice	1.00
CY2024Q3	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-8
CY2024Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2024Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z4BTsd2pIMKe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zE8yFyQyyGxf">Correction of an Immaterial Error in the Prior Period Financial Statements</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During the fourth quarter of 2023, the Company determined that the prior year consolidated financial statements had a misstatement caused by an immaterial classification error of certain research and development expenses in accordance with Accounting Standards Codification (“ASC”) 730. As a result, certain prior year amounts have been corrected for consistency with the current year presentation. The Company assessed the materiality of this change in presentation on prior period consolidated financial statements in accordance with SEC Staff Accounting Bulletin No. 99, “Materiality,” (ASC Topic 250, Accounting Changes and Error Corrections). Based on this assessment, the Company concluded that these error corrections in its unaudited condensed consolidated statements of operations are not material to any previously presented financial statements based upon overall considerations of both quantitative and qualitative factors. The corrections had no impact on the unaudited condensed consolidated balance sheet, unaudited condensed consolidated statements of cash flows, or unaudited condensed consolidated statement of changes in stockholders’ equity, to these financial statements, or for any previously presented interim or annual financial statements. Further, the corrections did not result in a change in quarterly or year-to-date operating losses, basic or diluted earnings per share, or working capital. The quarterly correction required for the three and nine months ended September 30, 2023 was $<span id="xdx_901_eus-gaap--GeneralAndAdministrativeExpense_c20240701__20240930__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_z6lhCptcdRek" title="General and administrative expense">95,129</span> and $<span id="xdx_90D_eus-gaap--GeneralAndAdministrativeExpense_c20240101__20240930__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_z8fii4jN2L3c" title="General and administrative expense">277,844</span>, respectively. Accordingly, the Company corrected the previously reported immaterial error for the three and nine months ended September 30, 2023 in this Quarterly Report on Form 10-Q.</span></p> <p id="xdx_896_eus-gaap--ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock_z9tVva8hTmMj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span><span id="xdx_8B6_z4EiZ6rbAhkg" style="display: none">Schedule of the Error Correction</span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49A_20230101__20230930__srt--RestatementAxis__srt--ScenarioPreviouslyReportedMember_zxwrWghFyWDe" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_49D_20230101__20230930__srt--RestatementAxis__srt--RevisionOfPriorPeriodErrorCorrectionAdjustmentMember_zZXABwLusoW8" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Correction</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt; font-weight: bold"> </td> <td colspan="2" id="xdx_493_20230101__20230930_zQLqKoHf4zf4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corrected <br/> September 30, 2023</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40E_eus-gaap--ResearchAndDevelopmentExpense_zPh05ROzFrUk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 46%; text-align: left">Research and development expense</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,084,488</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(277,844</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,806,644</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--GeneralAndAdministrativeExpense_za7WGaeI3Jea" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">General and administrative expense</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">452,342</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">277,844</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">730,186</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--ProfitLoss_zrkZIMvQIq46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Net Loss</td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,536,830</td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0704">-</span></td><td style="text-align: left"> </td><td> </td> <td style="border-bottom: Black 1pt solid; text-align: left">$</td><td style="border-bottom: Black 1pt solid; text-align: right">3,536,830</td><td style="text-align: left"> </td></tr> </table> <p id="xdx_8A7_zZXFZiliGROk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2806644	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	730186	usd
	us-gaap	Profit Loss ProfitLoss	3536830	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84B_eus-gaap--UseOfEstimates_z4QhNJmGARt" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span id="xdx_86B_zG7h4Bv69FJ">Use of Estimates</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates are contained in the accompanying unaudited condensed consolidated financial statements for the recognition of research and development expenses, valuation of warrants and valuation of bifurcated derivative liabilities and other financial instruments.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q3	us-gaap	Cash Cash	155652	usd
CY2023Q4	us-gaap	Cash Cash	1550098	usd
CY2024Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1004	usd
CY2023Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	1026318	usd
CY2024Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	156656	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2576416	usd
CY2024Q3	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q3	us-gaap	Cash Uninsured Amount CashUninsuredAmount	0	usd
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	2900000	usd
CY2024Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2524	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	20765	usd
CY2024Q3	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	56398	usd
CY2024Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-42898	usd
CY2023Q3	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	9606	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	38135	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	56720	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	100118	usd
	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1744	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-71568	usd
	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	21134	usd
CY2024Q3	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	74107	usd
CY2023Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	2887215	usd
CY2023Q4	us-gaap	Liabilities Fair Value Disclosure LiabilitiesFairValueDisclosure	414512	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	225338	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	342735	shares
	us-gaap	Operating Lease Payments Use OperatingLeasePaymentsUse	6480	usd
	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2023-10-31
CY2024Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	22947	usd
CY2023Q3	us-gaap	Operating Lease Cost OperatingLeaseCost	40491	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	68841	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	83230	usd
CY2024Q3	us-gaap	Variable Lease Cost VariableLeaseCost	10440	usd
CY2023Q3	us-gaap	Variable Lease Cost VariableLeaseCost	10408	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	30817	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	13723	usd
CY2024Q3	us-gaap	Sublease Income SubleaseIncome	2163	usd
CY2023Q3	us-gaap	Sublease Income SubleaseIncome	2135	usd
	us-gaap	Sublease Income SubleaseIncome	6489	usd
	us-gaap	Sublease Income SubleaseIncome	6377	usd
CY2024Q3	us-gaap	Lease Cost LeaseCost	31224	usd
CY2023Q3	us-gaap	Lease Cost LeaseCost	48764	usd
	us-gaap	Lease Cost LeaseCost	93169	usd
	us-gaap	Lease Cost LeaseCost	90576	usd
CY2024Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	23156	usd
CY2023Q3	us-gaap	Operating Lease Payments OperatingLeasePayments	31113	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	68345	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	73884	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	365556	usd
CY2024Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y11M1D
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M1D
CY2024Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1048	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1048	pure
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	23156	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	94247	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	97074	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	99986	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	68235	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	382698	usd
CY2024Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	68441	usd
CY2024Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	314257	usd
	us-gaap	Debt Instrument Maturity Date Description DebtInstrumentMaturityDateDescription	In December of 2021, the maturity dates of these loans were further extended to June 30, 2022. In July of 2022, the notes were extended to June 30, 2023.
CY2024Q3	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	10000000.0	usd
CY2024Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	345139	usd
CY2024Q3	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	22724	usd
CY2024Q3	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	367863	usd
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	846806	usd
	us-gaap	Debt Instrument Periodic Payment Interest DebtInstrumentPeriodicPaymentInterest	79682	usd
	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	926488	usd
CY2024Q3	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	762186	usd
	us-gaap	Debt Securities Gain Loss DebtSecuritiesGainLoss	833501	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	623465	usd
	us-gaap	Interest Expense InterestExpense	1952147	usd
CY2023Q3	us-gaap	Interest Expense Debt InterestExpenseDebt	538302	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	1550479	usd
CY2023Q3	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	331800	usd
	us-gaap	Debt Instrument Periodic Payment Principal DebtInstrumentPeriodicPaymentPrincipal	1925700	usd
CY2023Q3	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	54096	usd
	us-gaap	Debt Instrument Increase Accrued Interest DebtInstrumentIncreaseAccruedInterest	294927	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.93
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	127260	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.93
CY2024Q3	SHPH	Share Based Compensation Arrangement By Share Based Payment Award Non Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsOutstandingIntrinsicValue	0	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	2250000	usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Description ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription	(i) one share of the Company’s common stock, (ii) a warrant to purchase one share of the Company’s common stock exercisable at a purchase price of $18.80 per share, and (iii) a percentage of equity interest in Diagnostics such that, assuming the sale of all $2,250,000 of Units, SRO LLC will own a 22% interest in Diagnostics.
CY2024Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4500000	usd
CY2024Q1	us-gaap	Sale Of Stock Consideration Received Per Transaction SaleOfStockConsiderationReceivedPerTransaction	2250000	usd
CY2024Q2	us-gaap	Direct Operating Costs DirectOperatingCosts	142000	usd
CY2024Q3	us-gaap	Deferred Costs Current DeferredCostsCurrent	101651	usd
CY2023Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	127260	shares
CY2023Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1.93
CY2023Q1	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1189000	usd
CY2024Q3	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	74107	usd
CY2023Q1	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	2631000	usd
CY2024Q3	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	74107	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	0	usd
	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1058348	usd

Files In Submission

Name	View Source	Status
0001493152-24-045176-index-headers.html	Edgar Link	pending
0001493152-24-045176-index.html	Edgar Link	pending
0001493152-24-045176.txt	Edgar Link	pending
0001493152-24-045176-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
shph-20240930.xsd	Edgar Link	pending
shph-20240930_def.xml	Edgar Link	unprocessable
shph-20240930_lab.xml	Edgar Link	unprocessable
shph-20240930_pre.xml	Edgar Link	unprocessable
shph-20240930_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2024 Q4 Form 10-Q Financial Statement

#000149315224045176 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH Shuttle Pharmaceuticals Holdings, Inc. Stock $shph

2024 Q4 Form 10-Q Financial Statement

#000149315224045176 Filed on November 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SHPH
Shuttle Pharmaceuticals Holdings, Inc. Stock $shph